Mahmood, E., Hilal, N. (2024). Role of Melatonin in the Onset of Metabolic Syndrome in Men. Alustath, (), 66-71. doi: 10.33899/iraqij.p.2024.147371.1089
Elham Hasan Mahmood; Nihad Nejres Hilal. "Role of Melatonin in the Onset of Metabolic Syndrome in Men". Alustath, , , 2024, 66-71. doi: 10.33899/iraqij.p.2024.147371.1089
Mahmood, E., Hilal, N. (2024). 'Role of Melatonin in the Onset of Metabolic Syndrome in Men', Alustath, (), pp. 66-71. doi: 10.33899/iraqij.p.2024.147371.1089
Mahmood, E., Hilal, N. Role of Melatonin in the Onset of Metabolic Syndrome in Men. Alustath, 2024; (): 66-71. doi: 10.33899/iraqij.p.2024.147371.1089

Role of Melatonin in the Onset of Metabolic Syndrome in Men

Iraqi Journal of Pharmacy
Articles in Press, Accepted Manuscript, Available Online from 03 April 2024    PDF (602.29 K)
Document Type: Research Paper
DOI: 10.33899/iraqij.p.2024.147371.1089
Authors
Elham Hasan Mahmood* ; Nihad Nejres Hilal
College of Medicine, Tikrit University, Tikrit, Iraq
Abstract
Background:  This prospective hospital-based study conducted in Tikrit City (Iraq) aimed to investigate the role of melatonin and the level of haemoglobin A1c and lipid profile concentrations in metabolic syndrome patients. The present study sought to identify the role of serum melatonin in MetS male patients. Methods: Participants were all males aged 18-50 years. A total of 60 metabolic syndrome male patients versus 30 healthy control male participants were enrolled in the present study. Blood samples were collected at a specific time (10 P.M. to 1 A.M.) and analyzed for measurement of haemoglobin A1c, lipid profile and melatonin. Results: Melatonin is significantly (p>0.001) lower in patients with metabolic syndrome (206.55 ±105 pg/ml) compared with the control group (298.82±110.4 pg/ml).  The metabolic syndrome has significantly (p >0.001) elevated HbA1c % and lipid profile compared with the control group. Conclusion: In metabolic syndrome patients, serum melatonin concentration is reduced alongside elevated lipid profile glycemic control compared to normal people, these characteristics could participate in further enhancing the underlying pathology of metabolic syndrome diseases.
Keywords
Melatonin; Metabolic syndrome; HbA1c; Lipid profile
References
  1. Asato CB, Nelson-Hurwitz DC, Lee T, Grandinetti A. Comparative analysis of metabolic syndrome diagnostic criteria and its effects on prevalence in a multiethnic population. Metabolic Syndrome and Related Disorders. 2021;19(6):347-51.
  2. Sarhat ER, Wadi SA, Sedeeq BI, Sarhat TR, Jasim NA. Study of the histopathological and biochemical effect of Punica granatum L. extract on streptozotocin-induced diabetes in rabbits. Iraqi Journal of Veterinary Sciences. 2019;33(1):189-194.
  3. Jepsen S, Suvan J, Deschner J. The association of periodontal diseases with metabolic syndrome and obesity. Periodontology 2000. 2020;83(1):125-53.
  4. Sarhat KG, Jabir TH. Assessment of melatonin and oxidant-antioxidant markers in infertile men in Thi-Qar Province. Indian Journal of Forensic Medicine & Toxicology. 2019;13(4):1500-4.
  5. Saleh SS, Sarhat ER. Effects of ethanolic Moringa oleifera extract on melatonin, liver and kidney function tests in alloxan-induced diabetic rats. Indian Journal of Forensic Medicine & Toxicology. 2019;13(4):1015-9.
  6. Horodincu L, Solcan C. Influence of different light spectra on melatonin synthesis by the pineal gland and influence on the immune system in chickens. Animals. 2023;13(13):2095.
  7. Boiko DI, Shkodina AD, Hasan MM, Bardhan M, Kazmi SK, Chopra H, et al. Melatonergic receptors (Mt1/Mt2) as a potential additional target of novel drugs for depression. Neurochemical Research. 2022;47(10):2909-24.
  8. Corbalán-Tutau D, Madrid JA, Nicolás F, Garaulet M. Daily profile in two circadian markers “melatonin and cortisol” and associations with metabolic syndrome components. Physiology & behavior. 2014;123:231-5.
  9. Demirtas CY, Pasaoglu OT, Bircan FS, Kantar S, Turkozkan N. The investigation of melatonin effect on liver antioxidant and oxidant levels in fructose-mediated metabolic syndrome model. European Review for Medical and Pharmacological Sciences. 2015;19(10):1915-21.
  10. Cardinali DP, Hardeland R. Inflammaging, metabolic syndrome and melatonin: a call for treatment studies. Neuroendocrinology. 2017;104(4):382-97.
  11. Cardinali DP, Scacchi Bernasconi PA, Reynoso R, Reyes Toso CF, Scacchi P. Melatonin may curtail the metabolic syndrome: studies on initial and fully established fructose-induced metabolic syndrome in rats. International Journal of Molecular Sciences. 2013;14(2):2502-14.
  12. Prunet-Marcassus B, Desbazeille M, Bros A, Louche K, Delagrange P, Renard P, et al. Melatonin reduces body weight gain in Sprague Dawley rats with diet-induced obesity. Endocrinology. 2003;144(12):5347-52.
  13. Puchalski SS, Green JN, Rasmussen DD. Melatonin effect on rat body weight regulation in response to high-fat diet at middle age. 2003;21:163-7.
  14. Sartori C, Dessen P, Mathieu C, Monney A, Bloch J, Nicod P, et al. Melatonin improves glucose homeostasis and endothelial vascular function in high-fat diet-fed insulin-resistant mice. Endocrinology. 2009;150(12):5311-7.
  15. Ladizesky MG, Boggio V, Albornoz LE, Castrillón PO, Mautalen C, Cardinali DP. Melatonin increases oestradiol‐induced bone formation in ovariectomized rats. Journal of pineal research. 2003;34(2):143-51.
  16. Sanchez-Mateos S, Alonso-Gonzalez C, Gonzalez A, Martinez-Campa CM, Mediavilla MD, Cos S, et al. Melatonin and estradiol effects on food intake, body weight, and leptin in ovariectomized rats. Maturitas. 2007;58(1):91-101.
  17. Ciortea R, Costin N, Braicu I, Haragâş D, Hudacsko A, Bondor C, et al. Effect of melatonin on intra-abdominal fat in correlation with endometrial proliferation in ovariectomized rats. Anticancer research. 2011;31(8):2637-43.
  18. Ríos‐Lugo MJ, Cano P, Jiménez‐Ortega V, Fernández‐Mateos MP, Scacchi PA, Cardinali DP, et al. Melatonin effect on plasma adiponectin, leptin, insulin, glucose, triglycerides and cholesterol in normal and high fat–fed rats. Journal of pineal research. 2010;49(4):342-8.
  19. Nduhirabandi F, Du Toit EF, Blackhurst D, Marais D, Lochner A. Chronic melatonin consumption prevents obesity‐related metabolic abnormalities and protects the heart against myocardial ischemia and reperfusion injury in a prediabetic model of diet‐induced obesity. Journal of pineal research. 2011;50(2):171-82.
  20. Hatzis G, Ziakas P, Kavantzas N, Triantafyllou A, Sigalas P, Andreadou I, et al. Melatonin attenuates high fat diet-induced fatty liver disease in rats. World Journal of Hepatology. 2013;5(4):160.
  21. Pai SA, Majumdar AS. Protective effects of melatonin against metabolic and reproductive disturbances in polycystic ovary syndrome in rats. Journal of Pharmacy and Pharmacology. 2014;66(12):1710-21.
  22. Tutuncu NB, Batur MK, Yildirir A, Tutuncu T, Deger A, Koray Z, et al. Melatonin levels decrease in type 2 diabetic patients with cardiac autonomic neuropathy. Journal of pineal research. 2005;39(1):43-9.
  23. Peschke E, Stumpf I, Bazwinsky I, Litvak L, Dralle H, Mühlbauer E. Melatonin and type 2 diabetes–a possible link?. Journal of pineal research. 2007;42(4):350-8.
  24. Prokopenko I, Langenberg C, Florez JC, Saxena R, Soranzo N, Thorleifsson G, et al. Variants in MTNR1B influence fasting glucose levels. Nature genetics. 2009;41(1):77-81.
  25. Zheng C, Dalla Man C, Cobelli C, Groop L, Zhao H, Bale AE, et al. A common variant in the MTNR1b gene is associated with increased risk of impaired fasting glucose (IFG) in youth with obesity. Obesity. 2015;23(5).
  26. Song X, Sun X, Ma G, Sun Y, Shi Y, Du Y, et al. Family association study between melatonin receptor gene polymorphisms and polycystic ovary syndrome in Han Chinese. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2015;195:108-12.
  27. Domínguez‐Rodríguez A, Abreu‐González P, García MJ, Sanchez J, Marrero F, Armas‐Trujillo DD. Decreased nocturnal melatonin levels during acute myocardial infarction. Journal of pineal research. 2002;33(4):248-52.
  28. Yaprak M, Altun A, Vardar A, Aktoz M, Ciftci S, Ozbay G. Decreased nocturnal synthesis of melatonin in patients with coronary artery disease. International journal of cardiology. 2003;89(1):103-7.
  29. Obayashi K, Saeki K, Iwamoto J, Okamoto N, Tomioka K, Nezu S, et al. Nocturnal urinary melatonin excretion is associated with non-dipper pattern in elderly hypertensives. Hypertension Research. 2013;36(8):736-40.
  30. Goyal A, Terry PD, Superak HM, Nell-Dybdahl CL, Chowdhury R, Phillips LS, et al. Melatonin supplementation to treat the metabolic syndrome: a randomized controlled trial. Diabetology & metabolic syndrome. 2014;6:1-1.
  31. Koziróg M, Poliwczak AR, Duchnowicz P, Koter‐Michalak M, Sikora J, Broncel M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. Journal of pineal research. 2011;50(3):261-6.
  32. Mostafavi A, Solhi M, Mohammadi MR, Hamedi M, Keshavarzi M, Akhondzadeh S. Melatonin decreases olanzapine induced metabolic side-effects in adolescents with bipolar disorder: a randomized double-blind placebo-controlled trial. Acta Medica Iranica. 2014:734-9.
  33. Modabbernia A, Heidari P, Soleimani R, Sobhani A, Roshan ZA, Taslimi S, et al. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study. Journal of psychiatric research. 2014;53:133-40.
  34. Romo-Nava F, Alvarez-Icaza González D, Fresán-Orellana A, Saracco Alvarez R, Becerra-Palars C, Moreno J, et al. Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double‐blind, parallel‐group, placebo‐controlled clinical trial. Bipolar disorders. 2014;16(4):410-21.
  35. Hussain SA, Khadim HM, Khalaf BH, Ismail SH, Hussein KI, Sahib AS. Effects of melatonin and zinc on glycemic control in type 2 diabetic patients poorly controlled with metformin. Saudi medical journal. 2006;27(10):1483.
  36. Suriagandhi V, Nachiappan V. Protective effects of melatonin against obesity‐induced by leptin resistance. Behavioural brain research. 2022 Jan 24;417:113598.
  37. Chan K, Wong FS, Pearson JA. Circadian rhythms and pancreas physiology: A review. Frontiers in Endocrinology. 2022;13:920261.
  38. Ramirez AV, de Sá LB. Melatonin and its relationships with diabetes and obesity: a literature review. Current Diabetes Reviews. 2021;17(7):38-50.
  39. Farid A, Moussa P, Youssef M, Haytham M, Shamy A, Safwat G. Melatonin relieves diabetic complications and regenerates pancreatic beta cells by the reduction in NF-kB expression in streptozotocin induced diabetic rats. Saudi journal of biological sciences. 2022;29(7):103313.
  40. Nagagata BA, Ajackson M, Ornellas F, Mandarim-de-Lacerda CA, Aguila MB. Obese mothers supplemented with melatonin during gestation and lactation ameliorate the male offspring’s pancreatic islet cellular composition and beta-cell function. Journal of Developmental Origins of Health and Disease. 2023;14(4):490-500.
  41. Romejko K, Markowska M, Niemczyk S. The review of current knowledge on neutrophil gelatinase-associated lipocalin (NGAL). International Journal of Molecular Sciences. 2023;24(13):10470.
Statistics
Article View: 112
PDF Download: 51


Journal Management System. Powered by ejournalplus.com